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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
inhibiting cisplatin-induced death of 
cancer cells, raising the exciting possibility 
that cilastatin may protect patients from 
cisplatin-induced AKI without reducing 
its efficacy. See page 652.
Aldosterone signaling 
mediates Ang II toxicity
Angiotensin II (Ang II) antagonists are 
protective in many types of kidney dis-
ease, and these effects are mediated, in 
part, via reduced aldosterone receptor 
signaling. As they report in this issue, 
Luther et al. studied whether endogenous 
aldosterone synthesis is necessary for Ang 
II-induced renal injury. Aldosterone syn-
thase knockout and normal mice were 
subjected to Ang II infusion and high-
salt diet with or without aldosterone 
receptor blockade with spironolactone. 
The investigators found that aldosterone 
synthase knockout mice had reduced 
blood pressure and renal, cardiac, and 
vascular injury and that injury was further 
reduced by the addition of spironolactone. 
Cilastatin protects 
against cisplatin-
induced nephrotoxicity 
without compromising 
its anticancer efficiency 
in rats
Cisplatin is a chemotherapeutic medi-
cation with strong activity against many 
solid malignancies; however, its use is 
often limited by acute kidney injury 
(AKI). Although numerous studies have 
examined the mechanism of cisplatin-
induced AKI, there are no effective 
options to prevent or treat this compli-
cation. Humanes and co-workers dem-
onstrate that cilastatin, a small-molecule 
inhibitor of renal dehydropeptidase I, pre-
vents cisplatin-induced AKI in rats. Cilas-
tatin prevented cisplatin-induced decline 
in glomerular filtration rate, renal histo-
logic injury, tubular-cell apoptosis, and 
renal oxidative stress. Crucially, cilastatin 
exerted these protective effects without 
decreasing systemic cisplatin levels or 
This important study demonstrates that 
aldosterone receptor antagonism pro-
tects against Ang II–mediated injury via 
aldosterone synthase–dependent and 
independent pathways. See page 643.
The serum anion gap is 
altered in early kidney 
disease and associates 
with mortality
Elevated serum anion gap (AG) is known 
to occur in advanced kidney disease, but 
the prevalence of elevated AG in earlier 
stages of chronic kidney disease (CKD) 
is unknown. Abramowitz and colleagues 
analyzed data from National Health and 
Nutrition Examination Survey 1999–2004 
(NHANES) to determine the prevalence 
of AG elevations using three different for-
mulas in patients with estimated glomer-
ular filtration rate (eGFR) values greater 
than 15 ml/min/1.73 m2. They report that 
the traditional AG formula only identi-
fied elevated AG in patients with eGFR 
less than 45 ml/min/1.73 m2, whereas 
the albumin-adjusted and fully adjusted 
(potassium, calcium, albumin, and phos-
phate) formulas identified elevated AG at 
much higher levels of eGFR. Importantly, 
patients with elevated albumin-adjusted 
and fully adjusted AG—including those 
with early-stage CKD—had higher 
mortality than those with normal AG. 
See page 701.
